Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences.
Both the Veterans Administration Cooperative Study and the European Coronary Surgery Study have provided only brief accounts of graft patency rates in their surgically treated patients. In the Veterans Administration Cooperative Study, at an average of 1 year after operation, 69% of the grafts were patent among 208 patients; 88% of patients had at least one patent graft, and 58% had all grafts patent. In the European Coronary Surgery Study, angiographic examination of the grafts was performed within 9 months of operation in 84 patients, and showed a patency rate of 90%; in 223 patients, the examination was performed at between 9 and 18 months, and showed a 77% patency rate. In the Coronary Artery Surgery Study (CASS), graft patency rates were evaluated within 60 days of operation in 129 patients, a median of 18 months after operation in 121 patients, and a median of 5 years after operation in 197 patients. Cumulative vein graft patency (per distal anastomosis) was 90% early, 82% at 18 months, and 82% at 5 years. At least one graft anastomosis was patent early in 97% of patients, at 18 months in 96% of patients, and at 5 years in 97% of patients; all graft anastomoses were patent early in 81% of patients, at 18 months in 70% of patients, and at 5 years in 67% of patients. The incidence of vein graft stenosis of 50% or more was 10% at 18 months and 8% at 5 years after operation. The excellent results reported in CASS were associated with marked improvement in quality of life and excellent survival 5 years after operation in surgically treated patients, as previously reported.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass / Q000401:mortality; D004176:Dipyridamole / Q000627:therapeutic use; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D006965:Hyperplasia; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D011379:Prognosis; D012501:Saphenous Vein / Q000637:transplantation; D013997:Time Factors
D004176:Dipyridamole; D001241:Aspirin